Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer |
| |
| Authors: | Daniel H. Ahn Josh Reardon Chul W. Ahn Manojkumar Bupathi Sameh Mikhail Christina Sing‐Ying Wu Tanios Bekaii‐Saab |
| |
| Affiliation: | 1. Department of Internal Medicine, Mayo Clinic, Phoenix, AZ;2. Division of Hematology/Medical Oncology, Mayo Clinic, Phoenix, AZ;3. Department of Pharmacy, The Ohio State University, Columbus, OH;4. Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX;5. Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH;6. Zangmeister Cancer Center, Division of Hematology/Medical Oncology, Columbus, OH;7. Department of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, GA |
| |
| Abstract: | Treatment with cisplatin and gemcitabine demonstrates a survival benefit in patients with advanced biliary tract cancer (ABTC). However, the weekly administration can add significant toxicities that may prohibit prolonged treatment. Based on previous studies, we implemented a modified biweekly regimen of GC in an attempt to optimize the prescribed regimen with an improved toxicity profile, added convenience to patients while maintaining efficacy. Patients with ABTC were treated with fixed dose rate (FDR) gemcitabine (1,000 mg/m2/min) and cisplatin 20 mg/m2 on days 1 and 15 of every 28‐day cycle. Patients received treatment until time of progression, death, or discontinuation due to intolerance. Collected data included demographics, clinico‐pathologic features, toxicities, and survival. Kaplan‐Meier curves were used to calculate the median overall survival (OS) and progression free survival (PFS). The study included 107 evaluable pts with unresectable ABTC who received the biweekly regimen. Sites of tumor included gallbladder (21.5%), ampullary (3.7%), and bile duct (74.8%). Median number of cycles was 6 (1–27). Median PFS was 8.34 (6.74, 9.23) months and median OS was 10.32 (9.10, 11.43) months. Most common grade ≥3 adverse events included neutropenia (11%), fatigue (10%), and thrombocytopenia (6.4%). Biweekly FDR GC in ABTC is associated with a more favorable toxicity profile while maintaining efficacy similar to that observed in prior clinical trials. Minimal toxicities were observed despite a prolonged course for many patients. Further prospective trials should consider evaluating the role of biweekly GC regimen in ABTC, including a potentially more favorable platform in novel experimental strategies. |
| |
| Keywords: | biliary tract cancer modified regimen efficacious gemcitabine cisplatin improved toxicity profile |
|
|
